Ebola Vaccine Market driven by Growing Medical Research Sector worldwide | Key Players, Share, Trends, Applications, Forecast up to 2026

Ebola virus disease is one of the most deadly diseases and it affects human and nonhuman primates. It is a life-threatening disease caused by direct contact with the body fluid of an infected person. Fever, vomiting, sore throat, headache, diarrhea, and body pain are some of the most common symptoms of Ebola virus disease. There is no cure for Ebola virus disease however, the symptom can be controlled by maintaining electrolyte balance, imagining required oxygen level, and treating the infection. The vaccines to prevent Ebola virus disease are under development stage.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/1365

Rising cases of Ebola disease and growing initiatives for the development of vaccines are projected to fuel the market growth

Rising mortality rates due to Ebola is the prime factor fueling market growth. According to the World Health Organization, in January 2018, around 50% of people infected with EVD, have died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal, and Mali, Nigeria were affected with EVD. In 2014–16, an outbreak in West African countries such as Siberia, Leone, and Guinea, lead to deaths of around 11,300 individuals. Some cases were observed during the 2014–16 outbreak in the U.S., Spain, Italy, the U.K. among people that travelled to affected

African countries and people who came in contact with infected patients. In May 2017, the WHO declared an outbreak of EVD in the Democratic Republic of Congo. There is still fear about the potential outbreak of EVC in vulnerable regions of Western Africa which earlier faced EVD outbreak due to gaps in public health infrastructure. Various institutes and pharmaceutical companies are focusing on developing vaccines against EVD. According to a study published in the journal, The Lancet, in December 2016, rVSV-ZEBOV also known as V920 vaccine, which is jointly developed by Newlink Genetics and Merck and Company were found to be effective in protection against EVD in phase three trial. rVSV-ZEBOV uses a strain of Zaire Ebola virus. Merck is planning to file for final marketing approval of its EVD vaccine with the U.S. FDA in 2018. Moreover, it produced 3, 00,000 vaccines, in case of a fresh outbreak in vulnerable regions. Several key manufacturers are focusing on producing vaccines for EVD, in order to expand its market presence. For instance, GlaxoSmithKline developed the CAd3-ZEBOV vaccine, derived from chimpanzee adenovirus and was tested by the National Institute of Allergic and Infectious Disease, which started its phase three trials in February 2016. Janssen Pharmaceutical’s Ad26-ZEBOV is an experimental vaccine under development and currently in phase one. In 2014, Novavax Inc. developed the Ebola vaccine by using its proprietary recombinant technology.

Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1365

Market Segmentation

By virus strain, the global Ebola vaccine market is segmented into:

• Recombinant vesicular stomatitis virus-Zaire Ebola virus
• Chimpanzee Adeno virus type 3-Zaire Ebola virus
• Adeno virus serotype 26- Zaire Ebola Virus

In January 2018, GeoVax Labs Inc. published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus-like Particle (VLP) platform, which produces non-infectious VLPs in the body of the vaccinated individuals.

This VLP mimics the natural infection, which triggers the body to produce an immune response with both antibodies and T cells.GAVI is an international organization (global Vaccine Alliance) paid US$ 5 million to Merck & Company in 2016 for procurement of the vaccine (V 920 vaccine). Major players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, and Novavax Inc.

Other Related Reports:

ANTI-CATHEPSIN B MARKET ANALYSIS
PLANT-BASED VACCINES MARKET ANALYSIS
CATHEPSIN INHIBITORS MARKET ANALYSIS

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.